Skip to main content

Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)

SNRIs have seven off-label urologic applications: stress urinary incontinence (SUI) — the most-studied, with duloxetine approved for SUI in Europe but not the US; post-prostatectomy incontinence (PPUI); mixed urinary incontinence; overactive bladder; chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS); chronic pelvic pain in women; and premature ejaculation. Duloxetine is the dominant SNRI in urology — venlafaxine and milnacipran / levomilnacipran have limited urologic data and worse safety profiles. SNRIs also produce clinically important urologic adverse effects — urinary hesitation / retention (FDA warning) and sexual dysfunction — that urologists must actively recognize.[1][2][3]

For class-comparison context see Tricyclic antidepressants and Gabapentinoids. For the conditions and procedures these agents orbit, see Female SUI, Urethral Bulking Agents, Chronic Pelvic Pain, and IC/PBS.

Mechanism — Modulation of Onuf's Nucleus and the Continence Reflex​

Motor neurons in Onuf's nucleus (sacral spinal cord) control the external urethral sphincter (rhabdosphincter) and carry uniquely dense serotonergic and noradrenergic terminals. Duloxetine raises extracellular 5-HT and NE in the sacral spinal cord and produces three effects relevant to LUT function:[4][5][6][7]

  1. Facilitation of rhabdosphincter contraction during the storage phase — 5-HT and NE amplify the excitatory effect of glutamate on sphincter motor neurons. Critically, glutamate is the on/off switch — so duloxetine enhances sphincter activity during storage but allows complete relaxation during voiding, preserving bladder–sphincter synergy.[4][5]
  2. Suppression of bladder overactivity under irritated conditions — in animal models duloxetine produces dose-dependent increases in bladder capacity (up to 5×) and periurethral sphincter EMG activity (up to 8×), with minimal effect under normal conditions. Capacity effects are mediated through 5-HT receptors; sphincter facilitation involves 5-HT2 and α1-adrenergic mechanisms.[6]
  3. Enhanced active continence reflex — duloxetine increases urethral response amplitude during sneezing and Valsalva leak point pressure without significantly affecting urethral resting tone — i.e., it works on the active continence mechanism rather than passive tone.[4][7]

This is mechanistically distinct from TCAs: SNRIs lack antimuscarinic, antihistaminic, and direct smooth-muscle-relaxant activity, which makes the side-effect profile cleaner but the urologic utility narrower.[4][8]

SUI in Women — the principal urologic application​

Duloxetine is approved for SUI in Europe (Yentreve) but not in the US because of FDA suicide-risk concerns. The FDA label carries a specific warning about urinary hesitation and retention.[1][2] The NICE recommendation: offer duloxetine only after behavioral therapy fails and only when the woman prefers pharmacotherapy to surgery or is a poor surgical candidate.[1]

Cochrane review (10 RCTs, n = 3,944)[10]​

  • Subjective cure favored duloxetine (10.8% vs 7.7%; RR 1.42, 95% CI 1.02–1.98; p = 0.04) — small absolute effect (~3%)
  • ~50% reduction in incontinence episode frequency in individual studies
  • Significant QoL improvement (WMD I-QoL 4.5; p < 0.0001)

The ACP guideline (2014) characterized this as duloxetine "did not significantly improve UI" (NNT 13; 95% CI 7–143) with QoL benefit limited to non-severe SUI without OAB.[11]

Standard dosing for SUI​

  • 40 mg BID (80 mg/day total); some studies escalated to 120 mg/day
  • 80 mg/day is the optimal dose; 20–40 mg/day showed less consistent benefit[10]

Duloxetine + pelvic floor muscle training (PFMT)​

Combination therapy is additive — duloxetine pharmacologically enhances sphincter activity while PFMT strengthens the pelvic floor.[12][13][14]

TrialComparisonResult
Ghoniem 2005 (RCT, n = 201)Duloxetine + PFMT vs alone vs no treatment[14]Combination superior on IEF, pad use, and I-QoL
DULOXING 2021 (RCT, n = 158)Duloxetine + innovative PFMT vs duloxetine alone[12]IEF reduction 66.7% vs 50.0%; better ICIQ-SF, PGI-I 70.8% vs 65.6%, I-QoL +19.3% vs +6.6% (all p < 0.05)
Svihra 2021QALY analysis[13]Combination significantly increased QALYs vs duloxetine alone (17.90 vs 15.03; p < 0.05)

Sexual function​

Despite SNRIs' general association with sexual dysfunction, in 40 women with SUI on duloxetine 40 mg BID the mean FSFI total rose from 19.9 to 25.7 (p < 0.001) — likely an indirect effect of treating the incontinence and any concomitant depression.[15]

Post-Prostatectomy Incontinence​

There is no approved pharmacotherapy for PPUI. Duloxetine is the most-studied agent, used off-label.

Selected RCTs and series​

StudyDesignKey finding
Cornu 2011 (RCT, n = 31)[16]Duloxetine 80 mg/day vs placebo × 3 mo in post-RP SUIIEF reduction −52.2% vs +19.0% (MD 71.2%, p < 0.0001); I-QoL benefit
Filocamo 2007 (RCT, n = 112)[17]Duloxetine + rehab vs rehab alone × 16 wk post-catheterAt 16 wk, 39 vs 27 patients dry (p = 0.007). Critical caveat: at 20 wk after planned discontinuation, only 23 (duloxetine) vs 38 (rehab-only) were dry (p = 0.008) — duloxetine may mask rather than accelerate recovery
Sanchez-Salas 2024 (RCT, n = 240, 4-arm)[18]PFMT-biofeedback ± duloxetine vs controlAt 6 mo, control had highest continence (96%) vs PFMT-biofeedback 90%, duloxetine 73% (p = 0.008), combined 69% (p = 0.003); active treatments had worse QoL
Kang 2023 (retrospective, n = 197)[19]PFME + duloxetine 30 mg vs PFME aloneCombination better at 2 wk (p = 0.019); no difference at 3, 6, 9, or 12 mo
Schlenker 2006 (open-label, n = 20)[20]Duloxetine 80 mg/dayPad use 8.0 → 4.2/day (p < 0.001)
Collado Serra 2011 (open-label, n = 68, established PPUI)[21]Duloxetine in chronic (> 1 yr) PPUIICIQ-SF 13 → 9 (p < 0.001)

Practical interpretation​

Duloxetine provides short-term symptomatic improvement in PPUI but does not appear to accelerate true continence recovery. A reasonable role is as bridge therapy during early post-prostatectomy recovery — explicitly framed as such, with a stop date and not a substitute for PFMT or appropriate surgical referral.[22]

Mixed Urinary Incontinence​

The dual-mechanism rationale (sphincter facilitation for stress + indirect modulation of bladder overactivity for urge) is theoretically attractive. Two recent retrospective studies of duloxetine + tolterodine for urge-predominant mixed UI:

StudyNotes
Sobay 2025 (n = 106)[23]OABSS 11.08 → 6.95; ICIQ-SF 15.69 → 8.84; pads 3.58 → 0.73/day; capacity 315 → 436 mL (all p < 0.001)
Polat 2026 (n = 115)[24]Significant improvement in OABSS, ICIQ-SF, pad weights, frequency, nocturia, urgency, and IEF at weeks 4 and 12

Both retrospective and uncontrolled — prospective RCTs are needed before this becomes a recommended combination, but the signal is consistent and the mechanistic logic is sound.

Overactive Bladder​

Steers 2007 RCT[25]​

Duloxetine (80 → 120 mg/day) vs placebo in women with OAB symptoms (n = 306):

  • Significant reductions in voiding episodes / 24h, incontinence episodes / 24h, daytime voiding interval, and I-QoL at both dose levels
  • Urodynamics: no significant change in maximum cystometric capacity or volume threshold for DO — clinical benefit appears to come from central modulation, not direct detrusor effects
  • AEs: nausea (31%), dry mouth (16%), dizziness (14%), constipation (14%), insomnia (13%), fatigue (11%); PVR rose modestly (< 50 mL)

Multiple sclerosis OAB pilot (Di Rezze 2012)[26]​

Crossover trial in MS patients with OAB; significant improvement in OAB-Q with duloxetine vs both baseline and placebo.

Mechanistic preclinical data​

Duloxetine reverses detrusor overactivity and depression-like signs in a corticosterone-treated rat model via central pathways — distinct from solifenacin and mirabegron, which act peripherally. Effects persist 72 h after discontinuation, suggesting neuroplastic changes. Duloxetine may be uniquely suited to OAB co-existing with depression.[27][28] Convergent mouse data show SNRIs improve micturition control across multiple models.[9]

CP/CPPS​

Duloxetine has the strongest SNRI evidence in CP/CPPS.

StudyResult
Giannantoni 2014 (RCT, n = 38)[29]Duloxetine 60 mg + tamsulosin + saw palmetto vs tamsulosin + saw palmetto × 16 wk → significant improvement in NIH-CPSI pain, QoL, and total scores (p < 0.05)
Zhang 2017 (n = 153, three-arm)[30]Doxazosin + duloxetine vs doxazosin + sertraline vs doxazosin × 6 mo → response 88.6% vs 63.4% vs 56.1%; NIH-CPSI reduction 12.64 vs 7.41 vs 6.12 (p < 0.05)
Cochrane 2019[31]Antidepressants in CP/CPPS — low to very-low quality; AEs common

Duloxetine fits the multimodal UPOINT model (the "P" psychosocial domain or as a pain-modulating add-on), particularly when neuropathic features, anxiety, or depression are present. The Zhang result favoring duloxetine over sertraline aligns with the broader importance of noradrenergic mechanisms in pelvic pain.[30][32]

Chronic Pelvic Pain in Women​

The 2020 ACOG Practice Bulletin recommends SNRIs for neuropathic CPP at Level B, based on extrapolation from other neuropathic-pain conditions.[33]

  • A systematic review of 37 double-blind RCTs found SNRIs (and TCAs) were superior to placebo for depressive symptoms, pain, and QoL in neuropathic-pain syndromes (NNT 24 for clinical improvement)[33]
  • Cochrane shows duloxetine superior to placebo for diabetic neuropathy and fibromyalgia
  • No RCTs have established duloxetine or venlafaxine efficacy specifically in chronic pelvic pain in women
  • The 2021 JAMA CPP review concludes antidepressants provide only "minimal improvements in pain"[34]

ACOG prefers SNRIs over TCAs for neuropathic CPP because SNRIs also treat depressive symptoms and improve QoL with a cleaner side-effect profile.[33]

Premature Ejaculation​

SSRIs and SNRIs delay ejaculation pharmacologically. Dapoxetine, a short-acting SSRI, is the only serotonergic agent specifically approved (in Europe, not the US) for on-demand PE.[35][36]

Cochrane (31 RCTs, n = 8,254)[37]​

  • IELT increased by 3.09 minutes vs placebo (95% CI 1.94–4.25)
  • Perception of improvement: 2× more likely (NNT 5)
  • Satisfaction: RR 1.63; perceived control: RR 2.29
  • Paroxetine most effective long-acting SSRI (MD IELT +6.51 min)
  • Discontinuation due to AEs: NNH 33

Venlafaxine for PE — failed RCT​

Safarinejad 2008 (RCT, n = 222): venlafaxine 75 mg XR vs placebo × 12 weeks — no significant difference in IELT (1.7× vs 1.6×), intercourse satisfaction, or weekly coitus episodes. AEs more common with venlafaxine. Conclusion: "venlafaxine is not better than placebo in treatment of PE."[38]

Duloxetine for PE​

The 2022 AUA / SMSNA Disorders of Ejaculation Guideline lists duloxetine 40 mg/day and venlafaxine 75 mg/day as having a "limited evidence base" for PE.[39]

Dapoxetine​

Meta-analysis of 7 RCTs (n = 8,039): both 30 mg and 60 mg significantly improved IELT and PGIC vs placebo; 60 mg more effective but more AEs. Network meta-analysis ranked dapoxetine 30 mg as the most likely "best" pharmacologic PE intervention. Not available in the US.[40][41]

Bottom line​

Among SNRIs, duloxetine has limited evidence; venlafaxine failed in its only placebo-controlled trial. SSRIs (paroxetine for daily, dapoxetine for on-demand) have stronger evidence. SNRIs are not specifically recommended in the AUA guideline.[39][42]

Individual SNRI Profiles​

AgentUrologic roleNotable urologic AEs
DuloxetineSUI (EU-approved), PPUI bridge, mixed UI, OAB, CP/CPPS, CPP — the workhorse SNRI in urologyUrinary hesitation / retention (FDA warning); sexual dysfunction; nausea (~23%)[1][2]
VenlafaxineFailed PE RCT; no urologic-specific RCTsSexual dysfunction (ejaculatory delay, decreased libido, ED); urinary hesitation[38][43]
DesvenlafaxineNo urologic-specific dataSexual dysfunction; orthostatic hypotension in elderly
MilnacipranFibromyalgia (FDA-approved); pharmacovigilance data only in urologyDysuria, urinary retention, testicular pain, ejaculation disorders — FDA warning specifically about higher GU AEs in males with prostatic hypertrophy[44][45]
LevomilnacipranNo urologic-specific data; FAERS signal for urinary retention and painful ejaculation higher than milnacipran[44][46]Reflects greater NE selectivity

Urologic Adverse Effects​

Urinary hesitation and retention​

The duloxetine FDA label carries a specific warning: "Duloxetine is in a class of drugs known to affect urethral resistance. If symptoms of urinary hesitation develop during treatment, consideration should be given to the possibility that they might be drug-related." Post-marketing reports include retention requiring hospitalization and/or catheterization.[2]

A systematic review of RCTs found SNRIs caused voiding disorders more frequently than placebo (pooled OR 3.30; 95% CI 1.90–5.72; p < 0.001).[3]

Mechanism: SNRIs increase NE at the bladder neck and proximal urethra → increased urethral resistance → therapeutic for SUI but problematic in voiding dysfunction, BPH, or BOO.[8][46]

Management of SNRI-induced hesitation:[46]

  • Dose reduction or discontinuation usually relieves symptoms
  • Alpha-1A antagonist (tamsulosin) can relieve SNRI-induced hesitation within hours to days, allowing continued antidepressant therapy
  • Particularly relevant for levomilnacipran (most NE-selective)

The milnacipran label specifically warns that male patients with a history of obstructive uropathy may have higher GU AE rates.[45]

Sexual dysfunction​

All SNRIs carry FDA warnings about sexual dysfunction in both sexes — ejaculatory delay or failure, decreased libido, and ED in men; decreased libido and delayed or absent orgasm in women. Inquire about sexual function before starting and periodically during treatment.[2][43][45]

A FAERS pharmacovigilance analysis found levomilnacipran had higher rates of painful ejaculation and urinary retention than milnacipran, consistent with its greater NE selectivity.[44]

SIADH / hyponatremia​

All SNRIs can cause SIADH-mediated hyponatremia, particularly in older adults and patients on diuretics — relevant for urologic patients on thiazides for stone prevention or alpha-blockers for BPH.

Practical Prescribing for Urologists​

IndicationAgentStartTargetDuration
SUI (women)Duloxetine20 mg BID × 2 wk40 mg BID (80 mg/day)Ongoing[1][10]
PPUI (bridge)Duloxetine30 mg/day40 mg BID3–6 mo[16][17]
Mixed UIDuloxetine + tolterodineDuloxetine 40 mg BID + tolterodine 4 mg/daySame≥ 12 wk[23][24]
CP/CPPSDuloxetine30 mg/day × 1 wk60 mg/day4–6 mo[29][30]
CPP (women)Duloxetine30 mg/day60 mg/dayOngoing[33]
OABDuloxetine40 mg BID60 mg BID (120 mg/day)12 wk[25]

Cross-cutting precautions​

  • MAO inhibitors — contraindicated; serotonin syndrome; ≥ 14-day washout[2]
  • CYP1A2 / CYP2D6 inhibitors — fluvoxamine, ciprofloxacin, quinidine raise duloxetine levels[2]
  • Alpha-blockers — theoretical additive effect on urethral resistance with duloxetine + BPH alpha-blocker; conversely, tamsulosin can be used to manage SNRI-induced hesitation[46]
  • Anticoagulants / NSAIDs — increased bleeding risk; relevant perioperatively
  • Hepatic impairment — duloxetine contraindicated with substantial alcohol use or chronic liver disease[2]
  • Renal impairment — avoid duloxetine in severe renal impairment (CrCl < 30); milnacipran contraindicated in ESRD[2][45]

SNRIs vs TCAs vs Gabapentinoids — Quick Positioning​

FeatureSNRIs (duloxetine)TCAs (amitriptyline)Gabapentinoids
SUIPhase III RCTs; EU-approvedOff-label; no RCTsN/A
IC/BPSNo IC-specific dataAUA option (Grade B)[8]No IC-specific RCTs
OABRCT shows benefit; not in guidelinesImipramine useful adjunctPregabalin may help voided volume
CP/CPPSBest SNRI evidence — Giannantoni and ZhangUPOINT N domainPregabalin RCT failed primary
CPP (women)ACOG Level BWeak evidenceGaPP2 negative
Antimuscarinic effectsMinimalSignificantNone
SedationMinimalSignificantModerate
Cardiac riskMinimalQT prolongationMinimal
Overdose lethalityLowHighLow

Clinical Positioning​

  • Duloxetine is the workhorse SNRI in urology — the only one with phase III SUI RCT evidence (EU-approved; not US-approved); mechanism is sphincter facilitation through Onuf's-nucleus modulation, not detrusor relaxation[1][2][4]
  • SUI — modest objective benefit (~3% subjective-cure absolute increase in Cochrane); larger effect when combined with PFMT; reasonable when surgery is declined or contraindicated[10][12][14]
  • PPUI — bridge therapy, not a substitute for PFMT or surgery; the Filocamo "U-turn" and Sanchez-Salas negative results temper enthusiasm; frame the prescription with a stop date[17][18]
  • Mixed UI with duloxetine + antimuscarinic — promising but only retrospective data so far[23][24]
  • OAB — central, not peripheral, mechanism; particularly attractive when comorbid depression coexists[25][27]
  • CP/CPPS — best SNRI evidence; superior to sertraline in head-to-head; fits multimodal phenotype-directed therapy[29][30]
  • CPP in women — ACOG Level B for neuropathic phenotype but no women-specific RCTs and minimal pain effect in JAMA synthesis[33][34]
  • PE — venlafaxine failed; duloxetine has limited evidence; dapoxetine (SSRI) is the better-evidenced option (and not US-available)[37][38][39]
  • Urinary hesitation / retention is the most clinically important urologic AE — actively ask about SNRI use in patients with new voiding dysfunction; tamsulosin can rescue SNRI-induced hesitation if continuing the antidepressant matters[3][46]
  • Sexual dysfunction is common in both sexes — counsel before starting and ask about it on each visit[2][44]

See Also​

References​

1. Wu JM. "Stress incontinence in women." N Engl J Med. 2021;384(25):2428–2436. doi:10.1056/NEJMcp1914037

2. US Food and Drug Administration. Duloxetine — prescribing information. Updated 2025-11-14.

3. Trinchieri M, Perletti G, Magri V, et al. "Urinary side effects of psychotropic drugs: a systematic review and metanalysis." Neurourol Urodyn. 2021;40(6):1333–1348. doi:10.1002/nau.24695

4. Schuessler B. "What do we know about duloxetine's mode of action? Evidence from animals to humans." BJOG. 2006;113(Suppl 1):5–9. doi:10.1111/j.1471-0528.2006.00877.x

5. Thor KB. "Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence." Urology. 2003;62(4 Suppl 1):3–9. doi:10.1016/s0090-4295(03)00754-4

6. Thor KB, Katofiasc MA. "Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat." J Pharmacol Exp Ther. 1995;274(2):1014–1024.

7. Miyazato M, Kitta T, Kaiho Y, et al. "Effects of duloxetine on urethral continence reflex and bladder activity in rats with cerebral infarction." J Urol. 2015;194(3):842–847. doi:10.1016/j.juro.2015.03.091

8. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and treatment of interstitial cystitis/bladder pain syndrome." J Urol. 2022;208(1):34–42. doi:10.1097/JU.0000000000002756

9. Redaelli M, Ricatti MJ, Simonetto M, et al. "Serotonin and noradrenaline reuptake inhibitors improve micturition control in mice." PLoS One. 2015;10(3):e0121883. doi:10.1371/journal.pone.0121883

10. Mariappan P, Ballantyne Z, N'Dow JM, Alhasso AA. "Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults." Cochrane Database Syst Rev. 2005;(3):CD004742. doi:10.1002/14651858.CD004742.pub2

11. Qaseem A, Dallas P, Forciea MA, et al. "Nonsurgical management of urinary incontinence in women: a clinical practice guideline from the American College of Physicians." Ann Intern Med. 2014;161(6):429–440. doi:10.7326/M13-2410

12. Hagovska M, Svihra J, Breza J, Dubravicky J, Vargovcak M. "A randomized, intervention parallel multicentre study to evaluate duloxetine and innovative pelvic floor muscle training in women with uncomplicated stress urinary incontinence — the DULOXING study." Int Urogynecol J. 2021;32(1):193–201. doi:10.1007/s00192-020-04516-w

13. Svihra J, Hagovska M, Breza J, et al. "Impact of innovative pelvic floor muscle training on quality-adjusted life years (QALYs) in women with stress urinary incontinence treated by duloxetine." Eur J Obstet Gynecol Reprod Biol. 2021;264:25–30. doi:10.1016/j.ejogrb.2021.06.025

14. Ghoniem GM, Van Leeuwen JS, Elser DM, et al. "A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence." J Urol. 2005;173(5):1647–1653. doi:10.1097/01.ju.0000154167.90600.c6

15. Biyikoglu M, Kettas E, Sesli M, et al. "The effect of duloxetine on female sexual functions in the treatment of stress incontinence." Arch Gynecol Obstet. 2023;308(3):1037–1042. doi:10.1007/s00404-023-07123-4

16. Cornu JN, Merlet B, Ciofu C, et al. "Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial." Eur Urol. 2011;59(1):148–154. doi:10.1016/j.eururo.2010.10.031

17. Filocamo MT, Li Marzi V, Del Popolo G, et al. "Pharmacologic treatment in postprostatectomy stress urinary incontinence." Eur Urol. 2007;51(6):1559–1564. doi:10.1016/j.eururo.2006.08.005

18. Sanchez-Salas R, Tourinho-Barbosa R, Sivaraman A, et al. "Assessing the efficacy of pelvic floor muscle training and duloxetine on urinary continence recovery following radical prostatectomy: a randomized clinical trial." Prostate. 2024;84(2):158–165. doi:10.1002/pros.24634

19. Kang CS, Kim DH, Choi JH, et al. "Pelvic floor muscle exercise with or without duloxetine for postprostatectomy urinary incontinence: a retrospective single-center study." Medicine (Baltimore). 2023;102(32):e34657. doi:10.1097/MD.0000000000034657

20. Schlenker B, Gratzke C, Reich O, et al. "Preliminary results on the off-label use of duloxetine for the treatment of stress incontinence after radical prostatectomy or cystectomy." Eur Urol. 2006;49(6):1075–1078. doi:10.1016/j.eururo.2006.01.038

21. Collado Serra A, Rubio-Briones J, Puyol Payás M, et al. "Postprostatectomy established stress urinary incontinence treated with duloxetine." Urology. 2011;78(2):261–266. doi:10.1016/j.urology.2011.03.006

22. Castellan P, Ferretti S, Litterio G, Marchioni M, Schips L. "Management of urinary incontinence following radical prostatectomy: challenges and solutions." Ther Clin Risk Manag. 2023;19:43–56. doi:10.2147/TCRM.S283305

23. Sobay R, Küçük EV. "An investigation of the effect of combining tolterodine and duloxetine in the treatment of mixed-type urinary incontinence and the factors affecting success." J Clin Med. 2025;14(10):3575. doi:10.3390/jcm14103575

24. Polat H, Ekşi M, Çatık A, et al. "Clinical outcomes and safety of duloxetine and tolterodine combination in the treatment of mixed-type urinary incontinence: a single-arm retrospective study." J Int Med Res. 2026;54(3):3000605261430142. doi:10.1177/03000605261430142

25. Steers WD, Herschorn S, Kreder KJ, et al. "Duloxetine compared with placebo for treating women with symptoms of overactive bladder." BJU Int. 2007;100(2):337–345. doi:10.1111/j.1464-410X.2007.06980.x

26. Di Rezze S, Frasca V, Inghilleri M, et al. "Duloxetine for the treatment of overactive bladder syndrome in multiple sclerosis: a pilot study." Clin Neuropharmacol. 2012;35(5):231–234. doi:10.1097/WNF.0b013e3182613dce

27. Wróbel A, Serefko A, Woźniak A, et al. "Duloxetine reverses the symptoms of overactive bladder co-existing with depression via the central pathways." Pharmacol Biochem Behav. 2020;189:172842. doi:10.1016/j.pbb.2019.172842

28. Finnerup NB. "Nonnarcotic methods of pain management." N Engl J Med. 2019;380(25):2440–2448. doi:10.1056/NEJMra1807061

29. Giannantoni A, Porena M, Gubbiotti M, Maddonni S, Di Stasi SM. "The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome." Urology. 2014;83(2):400–405. doi:10.1016/j.urology.2013.09.024

30. Zhang M, Li H, Ji Z, Dong D, Yan S. "Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome: an observational study." Medicine (Baltimore). 2017;96(10):e6243. doi:10.1097/MD.0000000000006243

31. Franco JV, Turk T, Jung JH, et al. "Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome." Cochrane Database Syst Rev. 2019;10:CD012552. doi:10.1002/14651858.CD012552.pub2

32. Pena VN, Engel N, Gabrielson AT, Rabinowitz MJ, Herati AS. "Diagnostic and management strategies for patients with chronic prostatitis and chronic pelvic pain syndrome." Drugs Aging. 2021;38(10):845–886. doi:10.1007/s40266-021-00890-2

33. American College of Obstetricians and Gynecologists. "Chronic pelvic pain: ACOG Practice Bulletin, Number 218." Obstet Gynecol. 2020;135(3):e98–e109. doi:10.1097/AOG.0000000000003716

34. Lamvu G, Carrillo J, Ouyang C, Rapkin A. "Chronic pelvic pain in women: a review." JAMA. 2021;325(23):2381–2391. doi:10.1001/jama.2021.2631

35. Sunder M. "SSRIs and SNRIs for premature ejaculation in adult men." Am Fam Physician. 2022;105(6):591–592.

36. Hoy SM, Scott LJ. "Dapoxetine: in premature ejaculation." Drugs. 2010;70(11):1433–1443. doi:10.2165/11204750-000000000-00000

37. Sathianathen NJ, Hwang EC, Mian R, et al. "Selective serotonin re-uptake inhibitors for premature ejaculation in adult men." Cochrane Database Syst Rev. 2021;3:CD012799. doi:10.1002/14651858.CD012799.pub2

38. Safarinejad MR. "Safety and efficacy of venlafaxine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study." Andrologia. 2008;40(1):49–55. doi:10.1111/j.1439-0272.2008.00813.x

39. Shindel AW, Althof SE, Carrier S, et al. "Disorders of ejaculation: an AUA/SMSNA guideline." J Urol. 2022;207(3):504–512. doi:10.1097/JU.0000000000002392

40. De Hong C, Ren LL, Yu H, Qiang W. "The role of dapoxetine hydrochloride on-demand for the treatment of men with premature ejaculation." Sci Rep. 2014;4:7269. doi:10.1038/srep07269

41. Sridharan K, Sivaramakrishnan G, Sequeira RP, Al-Khaja KA. "Pharmacological interventions for premature ejaculation: a mixed-treatment comparison network meta-analysis of randomized clinical trials." Int J Impot Res. 2018;30(5):215–223. doi:10.1038/s41443-018-0030-x

42. Gul M, Bocu K, Serefoglu EC. "Current and emerging treatment options for premature ejaculation." Nat Rev Urol. 2022;19(11):659–680. doi:10.1038/s41585-022-00639-5

43. US Food and Drug Administration. Venlafaxine Hydrochloride — prescribing information. Updated 2026-04-10.

44. Huang T, Zhang P, Zhou Y, et al. "Disproportionality analysis of safety signals for milnacipran and levomilnacipran: a pharmacovigilance study using the FDA Adverse Event Reporting System." Front Pharmacol. 2025;16:1719881. doi:10.3389/fphar.2025.1719881

45. US Food and Drug Administration. Milnacipran Hydrochloride — prescribing information. Updated 2026-03-19.

46. Asnis GM, Caneva E, Henderson MA. "A review of antidepressant-induced urinary hesitancy: a focus on levomilnacipran ER including two case presentations." Expert Opin Drug Saf. 2016;15(5):717–725. doi:10.1517/14740338.2016.1164138